Albatira, Myline T.

HRN: 21-24-71  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/18/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
05/18/2022
05/24/2022
IVT
500mg 7 Doses
Q8
S/P Cesarean Section
Waiting Final Action 
05/18/2022
CEFUROXIME 750MG (VIAL)
05/18/2022
05/20/2022
IVT
750mg 6 Doses
Q8
S/P Cesarean Section
Waiting Final Action 
05/19/2022
CEFUROXIME 500MG (TAB)
05/19/2022
05/26/2022
PO
500mg
BID
Thickly MSAF
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: